These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 19322970)

  • 21. Research methods in drug surveillance.
    Engel RR; Grohmann R; Rüther E; Hippius H
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International monitoring for adverse drug reactions of long latency.
    Fletcher AP; Griffin JP
    Adverse Drug React Toxicol Rev; 1991; 10(4):209-30. PubMed ID: 1793771
    [No Abstract]   [Full Text] [Related]  

  • 23. Detection of adverse drug reaction signals using an electronic health records database: Comparison of the Laboratory Extreme Abnormality Ratio (CLEAR) algorithm.
    Yoon D; Park MY; Choi NK; Park BJ; Kim JH; Park RW
    Clin Pharmacol Ther; 2012 Mar; 91(3):467-74. PubMed ID: 22237257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compliance in European pharmacovigilance: a regulatory view.
    Arlett PR; Harrison P
    Pharmacoepidemiol Drug Saf; 2001; 10(4):301-2. PubMed ID: 11760490
    [No Abstract]   [Full Text] [Related]  

  • 25. [Drug-eruptions].
    Thielen AM; Toutous-Trellu L; Desmeules J
    Rev Med Suisse; 2008 Jul; 4(165):1671-5. PubMed ID: 18767294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How should we react to adverse drug reactions?
    Ferner RE; Beard K
    Postgrad Med J; 2011 Feb; 87(1024):81-2. PubMed ID: 21303818
    [No Abstract]   [Full Text] [Related]  

  • 27. Critical reflection on the collection and evaluation of adverse drug reaction data.
    Venulet J
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S48-53. PubMed ID: 3842691
    [No Abstract]   [Full Text] [Related]  

  • 28. Statewide test of a new postmarketing drug surveillance system.
    Fisher S; Bryant SG; Solovitz BL; Kluge RM
    Tex Med; 1987 Aug; 83(8):59-62. PubMed ID: 3660262
    [No Abstract]   [Full Text] [Related]  

  • 29. [PSUR - Instrument for pharmacovigilance and patient safety. What pharmacists should know about periodic safety update reports].
    Strehl E
    Med Monatsschr Pharm; 2009 Sep; 32(9):347-9. PubMed ID: 19795697
    [No Abstract]   [Full Text] [Related]  

  • 30. Adverse drug reactions.
    Turner P
    Hum Toxicol; 1986 May; 5(3):161-2. PubMed ID: 3710492
    [No Abstract]   [Full Text] [Related]  

  • 31. [The need for 'postmarketing surveillance'].
    Stricker BH; in 't Veld BA; Feenstra J
    Ned Tijdschr Geneeskd; 1999 Apr; 143(14):711-3. PubMed ID: 10347624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Propensity score methods in drug safety studies: practice, strengths and limitations.
    Wang J; Donnan PT
    Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497
    [No Abstract]   [Full Text] [Related]  

  • 33. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions.
    Fraunfelder FW; Fraunfelder FT
    Am J Ophthalmol; 2007 Jan; 143(1):145-149. PubMed ID: 17188050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Drug by drug imputation of adverse effects in drug monitoring. Attempted comparison of different methods].
    Lagier G; Vincens M; Lefebure B; Frelon JH
    Therapie; 1983; 38(3):295-302. PubMed ID: 6612666
    [No Abstract]   [Full Text] [Related]  

  • 35. The effect of backgrounds in safety analysis: the impact of comparison cases on what you see.
    Gogolak VV
    Pharmacoepidemiol Drug Saf; 2003; 12(3):249-52. PubMed ID: 12733479
    [No Abstract]   [Full Text] [Related]  

  • 36. The diagnosis of adverse medical events associated with drug treatment.
    Stephens MD
    Adverse Drug React Acute Poisoning Rev; 1987; 6(1):1-35. PubMed ID: 3303863
    [No Abstract]   [Full Text] [Related]  

  • 37. Misclassification in epidemiologic studies of adverse drug reactions using large managerial data bases.
    Graham DJ; Smith CR
    Am J Prev Med; 1988; 4(2 Suppl):15-24. PubMed ID: 3079350
    [No Abstract]   [Full Text] [Related]  

  • 38. [Pharmacovigilance in pharmacy practice].
    Duquet N
    J Pharm Belg; 2011 Dec; (4):97-103. PubMed ID: 22299235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. European drug agency criticises Roche for failing to report adverse reactions and patient deaths.
    Wise J
    BMJ; 2012 Jun; 344():e4344. PubMed ID: 22736470
    [No Abstract]   [Full Text] [Related]  

  • 40. Early postmarketing drug safety surveillance: data mining points to consider.
    Hauben M
    Ann Pharmacother; 2004 Oct; 38(10):1625-30. PubMed ID: 15304626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.